Intellia Therapeutics Closes Public Offering, Securing $194.6M to Fund Pipeline
Summary
Intellia Therapeutics has successfully closed its public offering, netting approximately $194.6 million in proceeds. This follows the company's announcement on April 29 of a $180 million public offering, which itself came shortly after highly positive Phase 3 results for its gene-editing therapy, lonvo-z. The capital raise, which included the full exercise of the underwriters' option, provides significant funding for advancing clinical programs, preparing for commercialization, and developing its pipeline. While dilutive, this substantial financing strengthens Intellia's balance sheet and extends its cash runway into 2028, enabling the company to capitalize on its recent clinical successes.
At the time of this announcement, NTLA was trading at $13.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.83 to $28.25. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.